专肽生物_定制多肽合成服务_多肽合成定制服务_多肽合成厂家_多肽合成公司

OVA G4 peptide 是激动剂卵白蛋白肽 SIINFEKL (OVA) (257-264) 的变体。SIINFEKL 通常用于刺激卵白蛋白特异性T细胞，并测试新的疫苗助剂是否能形成稳定的水凝胶。

OVA G4 peptide is a variant of the agonist ovalbumin (OVA) peptide SIINFEKL (257-264). SIINFEKL is routinely used to stimulate ovalbumin-specific T cells and to test new vaccine adjuvants can form a stable hydrogel.

G4 peptide acetate是激动剂卵清蛋白（OVA）肽（257-264）的变体。OVA肽是卵清蛋白的I类（Kb）限制性肽表位，由MHC（主要组织相容性复合体）分子H-2Kb（小鼠MHC的I类基因）表示。

G4 peptide acetate is a variant of the agonist ovalbumin (OVA) peptide (257-264). OVA Peptide is a class I (Kb)-restricted peptide epitope of ovalbumin, represented by an MHC (major histocompatibility complex) molecule H-2Kb (class I genes of the mouse MHC).

Peptide H-SIIGFEKL-OH is a Research Peptide with significant interest within the field academic and medical research. Recent citations using H-SIIGFEKL-OH include the following: Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses VT Colluru , CD Zahm , DG McNeel - Oncoimmunology, 2016 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1080/2162402X.2016.1223002 Suboptimal T-cell receptor signaling compromises protein translation, ribosome biogenesis, and proliferation of mouse CD8 T cells TCJ Tan , J Knight , T Sbarrato - Proceedings of the , 2017 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1700939114 Interferon-γ and interleukin-4 reciprocally regulate CD8 expression in CD8+ T cells SH Apte , A Baz, P Groves, A Kelso - Proceedings of the , 2008 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.0809549105 The tyrosine phosphatase PTPN22 discriminates weak self peptides from strong agonist TCR signals RJ Salmond , RJ Brownlie, VL Morrison - Nature , 2014 - nature.comhttps://www.nature.com/articles/ni.2958 Mechanistic target of rapamycin complex 1/S6 kinase 1 signals influence T cell activation independently of ribosomal protein S6 phosphorylation RJ Salmond , RJ Brownlie, O Meyuhas - The Journal of , 2015 - journals.aai.orghttps://journals.aai.org/jimmunol/article/195/10/4615/104772 Alteration of Cell Surface Sialylation RAIN CD - J Immunol, 2004 - academia.eduhttps://www.academia.edu/download/47694451/275.full.pdf Altered peptide ligands induce delayed CD8-T cell receptor interaction-a role for CD8 in distinguishing antigen quality PP Yachi, J Ampudia, T Zal , NRJ Gascoigne - Immunity, 2006 - cell.comhttps://www.cell.com/immunity/pdf/S1074-7613(06)00318-9.pdf Cytotoxic immunological synapses do not restrict the action of interferon-γ to antigenic target cells NSR Sanderson, M Puntel - Proceedings of the , 2012 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.1116058109 The strength of T cell receptor signal controls the polarization of cytotoxic machinery to the immunological synapse MR Jenkins , A Tsun , JC Stinchcombe, GM Griffiths - Immunity, 2009 - cell.comhttps://www.cell.com/immunity/pdf/S1074-7613(09)00412-9.pdf IL-12 enhances CTL synapse formation and induces self-reactivity MA Markiewicz , EL Wise, ZS Buchwald - The Journal of , 2009 - journals.aai.orghttps://journals.aai.org/jimmunol/article/182/3/1351/83625 The half-life of the T-cell receptor/peptide-major histocompatibility complex interaction can modulate T-cell activation in response to bacterial challenge LJ Carre , SM Bueno , P Bull, SG Nathenson - , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2567.2007.02561.x Targeted calcium influx boosts cytotoxic T lymphocyte function in the tumour microenvironment KD Kim, S Bae , T Capece, H Nedelkovska - Nature , 2017 - nature.comhttps://www.nature.com/articles/ncomms15365 Stored Fas ligand, a mediator of rapid CTL-mediated killing, has a lower threshold for response than degranulation or newly synthesized Fas ligand JS He, DE Gong, HL Ostergaard - The journal of immunology, 2010 - journals.aai.orghttps://journals.aai.org/jimmunol/article/184/2/555/111850 JNK2 negatively regulates CD8+ T cell effector function and anti-tumor immune response J Tao, Y Gao, MO Li , W He, L Chen - European journal of , 2007 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/eji.200636726 Contractile actomyosin arcs promote the activation of primary mouse T cells in a ligand-dependent manner J Hong , S Murugesan, E Betzig, JA Hammer - PLoS One, 2017 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0183174 Cbl-b mitigates the responsiveness of naive CD8+ T cells that experience extensive tonic T cell receptor signaling J Eggert, WM Zinzow-Kramer , Y Hu , EM Kolawole - Science , 2024 - science.orghttps://www.science.org/doi/abs/10.1126/scisignal.adh0439 CD69 does not affect the extent of T cell priming E Alari-Pahissa, L Notario, E Lorente , J Vega-Ramos - PLoS , 2012 - journals.plos.orghttps://journals.plos.org/plosone/article?id=10.1371/journal.pone.0048593 LPA5 is an inhibitory receptor that suppresses CD8 T-cell cytotoxic function via disruption of early TCR signaling D Mathew , KN Kremer, P Strauch, G Tigyi - Frontiers in , 2019 - frontiersin.orghttps://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2019.01159 Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells CD Zahm , VT Colluru , DG McNeel - Cancer immunology research, 2017 - AACRhttps://aacrjournals.org/cancerimmunolres/article-abstract/5/8/630/468807 Alteration of cell surface sialylation regulates antigen-induced naive CD8+ T cell responses BP Pappu, PA Shrikant - The Journal of Immunology, 2004 - journals.aai.orghttps://journals.aai.org/jimmunol/article/173/1/275/72999 ESCRT-mediated membrane repair protects tumor-derived cells against T cell attack AT Ritter , G Shtengel , CS Xu , A Weigel , DP Hoffman - Science, 2022 - science.orghttps://www.science.org/doi/abs/10.1126/science.abl3855 CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer AP Menon, H Villanueva, D Meraviglia-Crivelli - Therapy-Nucleic Acids, 2024 - cell.comhttps://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(24)00085-4 Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination AJ Litterman , AZ Dudek , DA Largaespada - Oncoimmunology, 2013 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.4161/onci.26294 Affinity thresholds for naive CD8+ CTL activation by peptides and engineered influenza A viruses AE Denton , R Wesselingh , S Gras - The Journal of , 2011 - journals.aai.orghttps://journals.aai.org/jimmunol/article/187/11/5733/85366 Hyperglycaemia does not affect antigen-specific activation and cytolytic killing by CD8+ T cells in vivo A Recino, K Barkan, FS Wong , G Ladds - Bioscience , 2017 - portlandpress.comhttps://portlandpress.com/bioscirep/article-abstract/37/4/BSR20171079/57449 N-hydroxy-amide analogues of MHC-class I peptide ligands with nanomolar binding affinities A Bianco , C Zabel, P Walden - of the European Peptide , 1998 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/(SICI)1099-1387(199812)4:8%3C471::AID-PSC166%3E3.0.CO;2-8

多肽H2N-Ser-Ile-Ile-Gly-Phe-Glu-Lys-Leu-COOH的合成步骤：

1、合成CTC树脂：称取2.95g CTC Resin（如初始取代度约为0.35mmol/g）和1.24mmol Fmoc-Leu-OH于反应器中，加入适量DCM溶解氨基酸（需要注意，此时CTC树脂体积会增大好几倍，避免DCM溶液过少），再加入3.1mmol DIPEA（Mw：129.1,d：0.740g/ml），反应2-3小时后，可不抽滤溶液，直接加入1ml的HPLC级甲醇，封端半小时。依次用DMF洗涤2次，甲醇洗涤1次，DCM洗涤一次，甲醇洗涤一次，DCM洗涤一次，DMF洗涤2次（这里使用甲醇和DCM交替洗涤，是为了更好地去除其他溶质，有利于后续反应）。得到  Fmoc-Leu-CTC Resin。结构图如下：

2、脱Fmoc：加3倍树脂体积的20%Pip/DMF溶液，鼓氮气30分钟，然后2倍树脂体积的DMF 洗涤5次。得到 H2N-Leu-CTC Resin 。（此步骤脱除Fmoc基团，茚三酮检测为蓝色，Pip为哌啶）。结构图如下：

3、缩合：取3.1mmol Fmoc-Lys(Boc)-OH 氨基酸，加入到上述树脂里，加适当DMF溶解氨基酸，再依次加入6.2mmol DIPEA，2.94mmol HBTU。反应30分钟后，取小样洗涤，茚三酮检测为无色。用2倍树脂体积的DMF 洗涤3次树脂。（洗涤树脂，去掉残留溶剂，为下一步反应做准备）。得到Fmoc-Lys(Boc)-Leu-CTC Resin。氨基酸：DIPEA：HBTU：树脂=3：6：2.85：1（摩尔比）。结构图如下：

4、依次循环步骤二、步骤三，依次得到

H2N-Lys(Boc)-Leu-CTC Resin

Fmoc-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

H2N-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

Fmoc-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

H2N-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

Fmoc-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

H2N-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

Fmoc-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

H2N-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

Fmoc-Ile-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

H2N-Ile-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

Fmoc-Ser(tBu)-Ile-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin

以上中间结构，均可在专肽生物多肽计算器-多肽结构计算器中，一键画出。

最后再经过步骤二得到 H2N-Ser(tBu)-Ile-Ile-Gly-Phe-Glu(OtBu)-Lys(Boc)-Leu-CTC Resin，结构如下：

5、切割：6倍树脂体积的切割液（或每1g树脂加8ml左右的切割液），摇床摇晃 2小时，过滤掉树脂，用冰无水乙醚沉淀滤液，并用冰无水乙醚洗涤沉淀物3次，最后将沉淀物放真空干燥釜中，常温干燥24小试，得到粗品H2N-Ser-Ile-Ile-Gly-Phe-Glu-Lys-Leu-COOH。结构图见产品结构图。

切割液选择：1）TFA：H2O=95%：5%、TFA：H2O=97.5%：2.5%

2）TFA：H2O：TIS=95%：2.5%：2.5%

3）三氟乙酸：茴香硫醚：1，2-乙二硫醇：苯酚：水=87.5%：5%：2.5%：2.5%：2.5%

（前两种适合没有容易氧化的氨基酸，例如Trp、Cys、Met。第三种适合几乎所有的序列。）

6、纯化冻干：使用液相色谱纯化，收集目标峰液体，进行冻干，获得蓬松的粉末状固体多肽。不过这时要取小样复测下纯度 是否目标纯度。

7、最后总结：

杭州专肽生物技术有限公司（ALLPEPTIDE https://www.allpeptide.com）主营定制多肽合成业务，提供各类长肽，短肽，环肽，提供各类修饰肽，如：荧光标记修饰（CY3、CY5、CY5.5、CY7、FAM、FITC、Rhodamine B、TAMRA等），功能基团修饰肽（叠氮、炔基、DBCO、DOTA、NOTA等），同位素标记肽（N15、C13），订书肽（Stapled Peptide）,脂肪酸修饰肽（Pal、Myr、Ste），磷酸化修饰肽（P-Ser、P-Thr、P-Tyr），环肽（酰胺键环肽、一对或者多对二硫键环），生物素标记肽，PEG修饰肽，甲基化修饰肽

以上所有内容，为专肽生物原创内容，请勿发布到其他网站上。